Abbott Laboratories (NYSE:ABT)’s traded shares stood at 2.31 million during the latest session, with the company’s beta value hitting 0.67. At the last check today, the stock’s price was $98.06, to imply a decrease of -0.98% or -$0.97 in intraday trading. The ABT share’s 52-week high remains $124.36, putting it -26.82% down since that peak but still an impressive 4.91% since price per share fell to its 52-week low of $93.25. The company has a valuation of $173.69B, with an average of 5.74 million shares in intraday trading volume over the past 10 days and average of 4.80 million shares over the past 3 months.
Analysts have given a consensus recommendation of an Overweight for Abbott Laboratories (ABT), translating to a mean rating of 2.00. Of 24 analyst(s) looking at the stock, 1 analyst(s) give ABT a Sell rating. 5 of those analysts rate the stock as Overweight while 6 advise Hold as 12 recommend it as a Buy. 0 analyst(s) have given it an Underweight rating. Estimates put the company’s current-quarter earnings per share at $0.99.
Do You Know The Best Place To Find Gains In Volatile Markets?
In today's chaotic marketplace, the biggest gains will come from some currently-small companies that pass by older, larger businesses still stuck in a pre-pandemic world. The trick is figuring out which small caps will be tomorrow's winners. That's why StockWire News has put together a special Wealth Building Report, highlighting 3 small cap stocks set to soar in 2023.
Click here for full details and to join for free.
Abbott Laboratories (NYSE:ABT) trade information
After registering a -0.98% downside in the latest session, Abbott Laboratories (ABT) has traded red over the past five days. The stock hit a weekly high of 99.50 this Thursday, 03/16/23, dropping -0.98% in its intraday price action. The 5-day price performance for the stock is 1.13%, and -8.59% over 30 days. With these gigs, the year-to-date price performance is -10.68%. Short interest in Abbott Laboratories (NYSE:ABT) saw shorts transact 14.6 million shares and set a 3.21 days time to cover.
Analysts on Wall Street suggest a consensus price target of $122.33, implying an increase of 19.84% to the stock’s recent value. The extremes give us $107.00 and $140.00 for target low and target high price respectively. As such, ABT has been trading -42.77% off suggested target high and -9.12% from its likely low.
Abbott Laboratories (ABT) estimates and forecasts
Looking at statistics comparing Abbott Laboratories share performance against respective industry, we note that the company has underperformed competitors. Abbott Laboratories (ABT) shares are -6.66% down over the last 6 months, with its year-to-date growth rate lower than industry average at -17.98% against 11.00%. Revenue is forecast to shrink -42.80% this quarter before falling -24.50% for the next one. The rating firms project that company’s revenue will shrink -8.30% compared to the previous financial year.
Revenue forecast for the current quarter as set by 15 analysts is $9.64 billion. Meanwhile, for the quarter ending Jun 2023, a total of 15 analyst(s) estimate revenue growth to $9.86 billion.Earnings reports from the last fiscal year show that sales brought in $11.89 billion and $11.26 billion respectively in the corresponding quarters. In this case, analysts estimate current quarter sales to fall -18.90% before dropping -12.40% in the following quarter.
An assessment of the company’s 5-year growth patterns shows that annual earnings grew an estimated 30.50% for the past 5-year period. While 2023 is set for a -0.60% return in earnings, projections for the next 5 years are at 8.30% annually.
Abbott Laboratories has its next earnings report out between April 18 and April 24. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too. Abbott Laboratories has a forward dividend ratio of 2.04, with the share yield ticking at 2.06% to continue the rising pattern observed over the past year. The company’s average dividend yield trailing the past 5-year period is 0.00%.
Abbott Laboratories (NYSE:ABT)’s Major holders
Abbott Laboratories insiders hold 0.73% of total outstanding shares, with institutional holders owning 75.94% of the shares at 76.50% float percentage. In total, 75.94% institutions holds shares in the company, led by Vanguard Group, Inc. (The). As of Sep 29, 2022, the company held over 154.56 million shares (or 8.86% of shares), all amounting to roughly $14.96 billion.
The next major institution holding the largest number of shares is Blackrock Inc. with 133.34 million shares, or about 7.65% of shares outstanding. As of the market price on Sep 29, 2022, these shares were worth $12.9 billion.
We also have Vanguard Total Stock Market Index Fund and Vanguard 500 Index Fund as the top two Mutual Funds with the largest holdings of the Abbott Laboratories (ABT) shares. Going by data provided on Sep 29, 2022, Vanguard Total Stock Market Index Fund holds roughly 52.25 million shares. This is just over 3.00% of the total shares, with a market valuation of $5.06 billion. Data from the same date shows that the other fund manager holds a little less at 39.7 million, or 2.28% of the shares, all valued at about 3.84 billion.